ICER Releases Final Report on Unsupported Price Increases in California
In the US, prescription drugs tend to increase in price faster than inflation and launch for prices far exceeding value to patients. In a newly released final report, ICER investigated unsupported price increases in California using data made available by SB-17, a law ensuring the transparency of drug costs from manufacturers and payers.